Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128569) titled 'Efficacy and Safety of Ruxolitinib Phosphate Cream Combined with Phototherapy in the Treatment of Non-Segmental Vitiligo: A Multicenter Real-World Study' on July 22.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Shanghai General Hospital
Condition:
Patients with non-segmental vitiligo involving facial lesions, whose total body depigmented area is no more than 10% BSA.
Intervention:
Control Group: Monotherapy Group(Treated with 1.5% ruxolitinib phosphate cream as monotherapy):None
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-07-24
Target Samp...